Gary A. Shangold

Dr. Shangold is Enteris BioPharma’s Chief Medical Officer, joining the Company in January 2020. He brings more than 25 years of pharmaceutical industry and consulting experience in clinical research and regulatory affairs.

Dr. Shangold is a seasoned industry professional having held C-suite level roles at a variety of innovative organizations. Prior to joining Enteris BioPharma, Dr. Shangold was the founder and CEO of InteguRx Therapeutics, a company developing transdermal pharmaceutical products. He was formerly Chief Medical Officer / Executive VP for R&D at Xanodyne Pharmaceuticals. Before that, he was President & CEO of NovaDel Pharma, a publicly-traded specialty pharma company. Earlier still, he worked at Johnson & Johnson Pharmaceutical R&D, where he held several senior roles in Clinical Research and Regulatory Affairs. Prior to J&J, Dr. Shangold was Medical Director of Ob/Gyn/Infertility at Serono Labs.

Before his 25 years in industry, Dr. Shangold spent a decade in academia, on the faculty of The University of Chicago Pritzker School of Medicine, and then later at Massachusetts General Hospital and the Harvard School of Medicine.

Dr. Shangold completed an Ob/Gyn residency at Jackson Memorial Hospital / University of Miami and a fellowship in Reproductive Endocrinology at the L.A. County / University of Southern California Medical Center. He received a BA in Social Behavior from the University of Pennsylvania, and an MD from the Columbia University College of Physicians and Surgeons.